Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04214249
Title BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)

acute myeloid leukemia


Cytarabine + Daunorubicin


Cytarabine + Idarubicin


Cytarabine + Daunorubicin + Pembrolizumab

Cytarabine + Pembrolizumab

Cytarabine + Idarubicin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Cancer Center Suspended Birmingham Alabama 35233 United States Details
UC Irvine Health/Chao Family Comprehensive Cancer Center Recruiting Orange California 92868 United States Details
Yale University Recruiting New Haven Connecticut 06520 United States Details
Mayo Clinic in Florida Recruiting Jacksonville Florida 32224-9980 United States Details
Northwestern University Recruiting Chicago Illinois 60611 United States Details
Dartmouth Hitchcock Medical Center Suspended Lebanon New Hampshire 03756 United States Details
Wake Forest University at Clemmons Recruiting Clemmons North Carolina 27012 United States Details
Wake Forest Baptist Health - Wilkes Medical Center Recruiting Wilkesboro North Carolina 28659 United States Details
Wake Forest University Health Sciences Recruiting Winston-Salem North Carolina 27157 United States Details
*Shaded cells indicate that there was no data available from for the field